Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $2.23 in the prior trading day, Agilon Health Inc (NYSE: AGL) closed at $2.25, up 0.90%. In other words, the price has increased by $0.90 from its previous closing price. On the day, 2.29 million shares were traded. AGL stock price reached its highest trading level at $2.32 during the session, while it also had its lowest trading level at $2.22.
Ratios:
Our goal is to gain a better understanding of AGL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.01.
On April 08, 2025, Bernstein Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $8.50.
Citigroup Upgraded its Sell to Neutral on January 10, 2025, whereas the target price for the stock was revised from $1.75 to $2.25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when McLoughlin Karen bought 25,000 shares for $2.20 per share. The transaction valued at 55,085 led to the insider holds 73,166 shares of the business.
Battaglia Silvana bought 25,062 shares of AGL for $50,269 on Dec 11 ’24. The Director now owns 66,144 shares after completing the transaction at $2.01 per share. On Nov 25 ’24, another insider, MCKENZIE DIANA, who serves as the Director of the company, bought 12,500 shares for $2.28 each. As a result, the insider paid 28,474 and bolstered with 51,319 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 931392000 and an Enterprise Value of 627024064. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.16 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 0.105 whereas that against EBITDA is -2.278.
Stock Price History:
The Beta on a monthly basis for AGL is 0.16, which has changed by -0.69839144 over the last 52 weeks, in comparison to a change of 0.10611236 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $7.73, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is -10.23%, while the 200-Day Moving Average is calculated to be -25.31%.
Shares Statistics:
The stock has traded on average 4.66M shares per day over the past 3-months and 2968710 shares per day over the last 10 days, according to various share statistics. A total of 413.02M shares are outstanding, with a floating share count of 303.70M. Insiders hold about 26.63% of the company’s shares, while institutions hold 73.51% stake in the company. Shares short for AGL as of 1749772800 were 21228626 with a Short Ratio of 4.47, compared to 1747267200 on 22198808. Therefore, it implies a Short% of Shares Outstanding of 21228626 and a Short% of Float of 8.3900005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Agilon Health Inc (AGL) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.13 and -$0.48 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.22, with 11.0 analysts recommending between -$0.01 and -$0.4.
Revenue Estimates
16 analysts predict $1.47B in revenue for the current quarter. It ranges from a high estimate of $1.5B to a low estimate of $1.46B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.48BFor the next quarter, 16 analysts are estimating revenue of $1.46B. There is a high estimate of $1.51B for the next quarter, whereas the lowest estimate is $1.43B.
A total of 19 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.03B, while the lowest revenue estimate was $5.9B, resulting in an average revenue estimate of $5.96B. In the same quarter a year ago, actual revenue was $6.06BBased on 19 analysts’ estimates, the company’s revenue will be $6.6B in the next fiscal year. The high estimate is $7.2B and the low estimate is $6.01B.
